Paclitaxel: Infusion Duration Effect on Toxicity and Efficacy

Ajani J.A. , Welch S.R. , Raber M.N. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8: 147–159.

Donehower R.C. , Rowinsky E.K. Paclitaxel. In: DeVita V.T. Jr. , Hellman S. , Rosenberg S.A. , eds. Principles and Practice of Oncology Updates. Philadelphia, Pa: JB Lippincott Co; 1994; 1–16.

Weiss R.B. , Donehower R.C. , Wiernik P.H. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990; 8: 1263–1268.

Arbuck S.G. , Canetta R. , Onetto N. Current dosage and schedule issues in the development of paclitaxel (taxol). Semin Oncol. 1989; 16(Suppl 4): 26–29.

Peereboom D.M. , Donehower R.C. , Eisenhauer E.A. Successful retreatment with Taxol after major hypersensitivity reactions. J Clin Oncol. 1993; 11: 885–890.

Swenerton K. , Eisenhauer E. , ten Bokkel Huinink W. Taxol in relapsed ovarian cancer: high vs low and short vs long infusion. Proc Annu Meet Am Soc Clin Oncol. 1993; 12: A256. Abstract.

Eisenhauer E. , Bacon M. , Darko E. A multicenter, randomized comparative study of Taxol in platinum treated ovarian cancer (high vs low; long vs short infusion): a European-Canadian multicenter trial coordinated by the NCI Canada Clinical Trials Group. Presented at the Annual Meeting of the National Cancer Institute of Canada; 1993; Montreal, Quebec, Canada.

Aisner J. , Albain K. , Belani C.P. Taxol (paclitaxel) for injection concentrate: clinical experience in an outpatient setting. (K4-W007) Princeton, NJ: Bristol-Myers Squibb, Inc; 1994: 13–14.

Rowinsky E.K. , Gilbert M.R. , McGuire W.P. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991; 9: 1692–1703.

LeBlanc G.A. , Sundseth S.S. , Weber G.F. Platinum anticancer drugs modulate P450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 1992; 52: 540–547.

Holmes F.A. , Walters R. , Valera V. The M.D. Anderson experience with Taxol in metastatic breast cancer. Proceedings of the Second NCI Workshop on Taxol and Taxus, Alexandria, Va, September 23–24, 1992. Abstract.

Wilson W.H. , Kang Y.K. , Bryant G. Phase I/II study of 96-hour infusional Taxol in refractory lymphomas and breast cancer. Proceedings of the Second NCI Workshop on Taxol and Taxus, Alexandria, Va, September 23–24, 1992. Abstract.

Schiller J.H. , Storer B. , Tutsch K. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994; 12: 241–248.

Apfel S.C. , Lipton R.B. , Arezzo J.C. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol. 1991; 29: 87–90.

Arbuck S.G. Paclitaxel: what schedule, what dose? J Clin Oncol. 1994; 12: 233–236.

Zhan Z. , Kang Y.K. , Regis J. Taxol resistance: in vitro and in vivo studies in breast cancer and lymphoma. Proc Annu Meet Am Assoc Cancer Res. 1993; 34: 215. Abstract.

Chervinsky D.S. , Brecher M.L. , Hoelcle M.J. Cremophor-EL reverses Taxol cross-resistance in murine C1300 multidrug-resistant neu-roblastoma cells. Proc Annu Meet Am Assoc Cancer Res. 1992; 33: 477. Abstract.

Fisher B. Phase III randomized study of high dose paclitaxel (Taxol) administered as a 3-hour vs a 24-hour infusion, both with GCSF support, in women with metastatic or locally advanced breast cancer. Protocol of National Surgical Adjuvant Breast and Bowel Project. Pittsburgh, Pa: University of Pittsburgh School of Medicine Department of Surgery (ongoing study).

Nabholtz J.M. , Gelmon K. , Bontenbal M. Randomized trial of two doses of Taxol in metastatic breast cancer: an interim analysis. Proc Annu Meet Am Soc Clin Oncol. 1993; 12: 60. Abstract.